scholarly journals Inhibition of renin activity by aliskiren ameliorates diabetic nephropathy in type 1 diabetes mouse model

2012 ◽  
Vol 02 (03) ◽  
pp. 353-360 ◽  
Author(s):  
Yan Zhang ◽  
Youli Wang ◽  
Yunzi Chen ◽  
Dilip K. Deb ◽  
Tao Sun ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Diabetic Nephropathy ◽  
Mouse Model ◽  
Renin Activity ◽  
Diabetes Mouse

scholarly journals TLR9-Deficiency in B Cells Promotes Immune Tolerance via IL-10 in a Type 1 Diabetes Mouse Model

Diabetes ◽  
2020 ◽  
pp. db200373
Author(s):  
Sha Sha ◽  
James A Pearson ◽  
Jian Peng ◽  
Youjia Hu ◽  
Juan Huang ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
B Cells ◽  
Mouse Model ◽  
Immune Tolerance ◽  
Diabetes Mouse

scholarly journals Macrophages from a type 1 diabetes mouse model present dysregulated Pl3K/AKT, ERK 1/2 and SAPK/JNK levels

Immunobiology ◽  
2020 ◽  
Vol 225 (2) ◽  
pp. 151879 ◽  
Author(s):  
Fernando Henrique Galvão Tessaro ◽  
Thais Soprani Ayala ◽  
Leonardo Mendes Bella ◽  
Joilson Oliveira Martins
Keyword(s):  
Type 1 Diabetes ◽  
Mouse Model ◽  
Diabetes Mouse

scholarly journals Altered bone microarchitecture in a type 1 diabetes mouse model Ins2 Akita

2018 ◽  
Vol 234 (6) ◽  
pp. 9338-9350 ◽  
Author(s):  
Filipe R. Carvalho ◽  
Sofia M. Calado ◽  
Gabriela A. Silva ◽  
Gabriela S. Diogo ◽  
Joana Moreira da Silva ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Mouse Model ◽  
Bone Microarchitecture ◽  
Diabetes Mouse

scholarly journals Senescence marker protein‐30/gluconolactonase deficiency exacerbates diabetic nephropathy through tubular injury in a mouse model of type 1 diabetes

2014 ◽  
Vol 6 (1) ◽  
pp. 35-43 ◽  
Author(s):  
Hiroshi Okada ◽  
Takafumi Senmaru ◽  
Michiaki Fukui ◽  
Yoshitaka Kondo ◽  
Akihito Ishigami ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Diabetic Nephropathy ◽  
Mouse Model ◽  
Marker Protein ◽  
Tubular Injury

scholarly journals Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes

2008 ◽  
Vol 295 (2) ◽  
pp. F605-F617 ◽  
Author(s):  
Hang Yuan ◽  
Linda Lanting ◽  
Zhong-Gao Xu ◽  
Shu-Lian Li ◽  
Piotr Swiderski ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Diabetic Nephropathy ◽  
Growth Factor ◽  
Mouse Model ◽  
Tissue Growth ◽  
Type I ◽  
Small Interfering Rnas ◽  
Matrix Deposition

We previously showed that the 12/15-lipoxygenase (12/15-LO) pathway of arachidonate acid metabolism is involved in multiple events related to diabetic nephropathy (DN), including glomerular hypertrophy and extracellular matrix deposition (Kang SW, Adler SG, Nast CC, LaPage J, Gu JL, Nadler JL, Natarajan R. Kidney Int 59: 1354–1362, 2001; Kang SW, Natarajan R, Shahed A, Nast CC, LaPage J, Mundel P, Kashtan C, Adler SG. J Am Soc Nephrol 14: 3178–3187, 2003; Kim YS, Lanting L, Adler SG, Natarajan R. Kindney Int 64: 1702–1714, 2003; Reddy MA, Adler SG, Kim YS, Lanting L, Rossi JJ, Kang SW, Nadler JL, Shahed A, Natarajan R. Am J Physiol Renal Physiol 283: F985–F994, 2002). In this study, we investigated whether in vivo delivery of small interfering RNAs (siRNAs) targeting 12/15-LO can ameliorate renal injury and DN in a streptozotocin-injected mouse model of type 1 diabetes. To achieve greater in vivo access and siRNA expression in the kidney, we used double-stranded 12/15-LO siRNA oligonucleotides conjugated with cholesterol. Diabetic DBA/2J mice were injected subcutaneously with either cholesterol-tagged 12/15-LO siRNA, mismatched control siRNA, or vehicle alone, twice weekly for 7 wk. Relative to controls, mice that received 12/15-LO siRNA showed significant reduction in albuminuria, kidney-to-body weight ratios, glomerular mesangial matrix expansion, renal structural damage, and monocyte/macrophage infiltration. These effects were associated with lower renal cortical or glomerular levels of profibrotic markers transforming growth factor-β, connective tissue growth factor, type I and type IV collagens, plasminogen activator inhibitor 1, and fibronectin. The diabetes-induced increase in glomerular cyclin-dependent kinase inhibitors that are associated with hypertrophy was also prevented by siRNA administration. Our results show for the first time that systemic delivery of cholesterol-tagged siRNAs targeting 12/15-LO has renoprotective effects under diabetic conditions and therefore could be a novel therapeutic approach for DN.

Sign in / Sign up

Export Citation Format

Share Document